Axoltis Pharma

Private

Clermont-FerrandHealthcare & Life Scienceshttps://www.axoltis.com/

Last Round

Series A

Dec 2, 2025

Est. Valuation

$37.63M

Total Funding Raised

$23.32M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Axoltis Pharma is a biotechnology company that develops innovative drugs for neurodegenerative and neurotraumatic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

ALSamyotrophic lateral sclerosisneurodegenerative diseaseclinical stage biotechpeptide therapeuticfirst-in-class drugblood-brain barrierneuroprotectionorphan drugpharma licensingdrug developmentBBBParkinson's diseaseAlzheimer's diseaseneurotherapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axoltis Pharma Comps

Public and private peers based on sector, stage, and business model.

Axoltis Pharma comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Axoltis Pharma Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Dec 2, 2025
Seed	Jun 15, 2016

View all Funding Rounds

Key People

Founding team and executive leadership

Luca Bolliger

Chief Business Officer, Independent Supervisory Board Member

Executive Team

Axoltis Pharma Investors

Notable investors and investment history

Axoltis Pharma investors
Investor	Rounds
ODDO BHF Group	Series A
UI Investissement	Seed
Angelor	Seed, Series A
Norfoalk	Series A
Sofimac Investment Managers	Seed, Series A
Capital Cell	Series A
UI Investissement	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Feb 22, 2026
Grew 21% QoQ, from 14 to 17 employees.
Dec 24, 2025
Grew 21% QoQ, from 14 to 17 employees.

View all signals

Axoltis Pharma Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Axoltis Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axoltis Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersClermont-Ferrand

Employee Range15

Year Founded2003

Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.